CASP14 Antibody

What is Caspase-14 and how does it differ from other caspases?

Caspase-14 belongs to the caspase family of cysteinyl aspartate-specific proteinases, but differs significantly from other family members. Unlike most caspases that function primarily in apoptosis across various tissues, Caspase-14 shows restricted expression in embryonic tissues and adult skin . A key molecular distinction is its proteolytic processing site - while conventional caspases are cleaved at aspartic acid residues, Caspase-14 undergoes processing at Ile152/Lys153 residues . This unique processing mechanism correlates with its specialized functions in keratinocyte differentiation rather than classical apoptosis pathways.

Structurally, Caspase-14 exists as an inactive proenzyme that requires proteolytic processing to generate functional large (p20) and small (p10) subunits . The molecular weight of human Caspase-14 is calculated at 28 kDa, though it often appears at approximately 35 kDa in Western blot analyses .

What are the primary physiological functions of Caspase-14?

Caspase-14 serves predominantly non-apoptotic functions in the epidermis. Research findings demonstrate its crucial roles in:

• Keratinocyte terminal differentiation and cornification required for skin barrier formation

• Proteolytic processing of filaggrin, essential for epidermal maturation

• DNA repair in epithelial tissues

• Processing of prosaposin in the epidermis

• DNA degradation in differentiated keratinocytes, likely through cleavage of DFFA/ICAD, leading to liberation of DFFB/CAD

• Maintenance of retinal pigment epithelium cell barrier function

Unlike typical caspases, Caspase-14 demonstrates substrate specificity for the [WY]-X-X-D motif and shows activity on the synthetic caspase substrate WEHD-ACF .

What disease conditions are associated with Caspase-14 dysregulation?

Several pathological conditions have been linked to abnormal Caspase-14 expression or function:

The role of Caspase-14 in carcinogenesis appears complex, with research suggesting both tumor-promoting and tumor-suppressive functions depending on cellular context .

What criteria should researchers use when selecting a Caspase-14 antibody?

When selecting a Caspase-14 antibody for research applications, consider these essential parameters:

• Host species and clonality: Both rabbit polyclonal and monoclonal antibodies are commercially available, each with distinct advantages. Polyclonal antibodies typically offer higher sensitivity through recognition of multiple epitopes, while monoclonals provide better specificity .

• Validated applications: Ensure the antibody has been validated for your specific application. Different Caspase-14 antibodies are optimized for:

  • Western Blot (WB): Typical dilutions range from 1:500-1:6000

  • Immunohistochemistry (IHC): Typical dilutions range from 1:50-1:200

  • Immunocytochemistry (ICC): Typical dilutions range from 1:50-1:200

  • Immunofluorescence (IF): Typical dilutions range from 1:50-1:200

  • Immunoprecipitation (IP): Typical dilutions around 1:50

  • Flow Cytometry (FC): Typical dilutions range from 1:50-1:100

  • ELISA: Various dilutions depending on specific protocol

• Species reactivity: Verify cross-reactivity with your experimental model. Many Caspase-14 antibodies react with human, mouse, and rat samples, but species reactivity should be confirmed .

• Immunogen information: Understanding the immunogen helps predict potential cross-reactivity and epitope accessibility in different experimental conditions. Antibodies may target synthetic peptides, recombinant proteins, or specific regions of Caspase-14 .

How should Caspase-14 antibodies be validated for specificity?

Rigorous validation is essential for obtaining reliable experimental results with Caspase-14 antibodies:

• Positive and negative control tissues: Skin tissue serves as an ideal positive control given the high expression of Caspase-14 in epidermis . Mouse and rat skin tissues have been successfully used to validate antibody specificity .

• Western blot validation: Confirm the antibody detects a band at the expected molecular weight (~28-35 kDa). Be aware that Caspase-14 may appear at different molecular weights depending on its processing state (full-length versus cleaved forms) .

• Knockout/knockdown controls: When possible, use CASP14 knockout or knockdown samples as negative controls to confirm specificity.

• Peptide competition assay: Pre-incubating the antibody with the immunizing peptide should abolish specific signals if the antibody is truly specific.

• Multiple detection methods: Validate findings using at least two different detection methods (e.g., WB and IHC) to increase confidence in specificity.

What are the optimal storage conditions for maintaining CASP14 antibody stability?

Based on manufacturer recommendations across multiple sources, the following storage conditions are optimal for maintaining Caspase-14 antibody stability and activity:

• Long-term storage: Store at -20°C or -80°C . Most formulations remain stable for at least one year when properly stored.

• Stabilizing agents: Most commercial antibodies are supplied in:

  • PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

  • PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

  • Similar buffers with cryoprotectants and preservatives

• Handling recommendations:

  • Avoid repeated freeze-thaw cycles

  • For frequent use, aliquot and store small volumes

  • Some 20μl sizes contain 0.1% BSA for added stability

  • For preservative-free formulations, adding sodium azide (final concentration 0.05%-0.1%) is recommended to prevent contamination

How can researchers differentiate between active and inactive forms of Caspase-14?

Distinguishing between the proenzyme (inactive) and cleaved (active) forms of Caspase-14 requires specific methodological approaches:

• Western blot analysis with carefully selected antibodies: Choose antibodies that can detect both the ~28-35 kDa full-length proenzyme and the processing products (p20 and p10 subunits) . This may require antibodies targeting different epitopes.

• Substrate-based activity assays: Caspase-14 has a preference for the [WY]-X-X-D motif and is active on the synthetic caspase substrate WEHD-ACF . Fluorogenic or chromogenic substrates can be used to detect catalytic activity.

• Protein processing analysis: Caspase-14 undergoes proteolytic processing at Ile152/Lys153 residues , unlike other caspases which are processed at Asp residues. Antibodies specifically recognizing these cleavage sites can help distinguish processed forms.

• Protein-protein interaction studies: Active Caspase-14 binds to the apoptosis-inducing factor (AIF) , which can be leveraged in co-immunoprecipitation experiments to isolate active forms.

• Cellular localization: Immunofluorescence studies targeting different epitopes can help identify localization patterns that correlate with activation state.

What methodological considerations are essential when studying CASP14 in skin models?

Investigating Caspase-14 in skin models presents unique challenges that require careful methodological planning:

• Sample preparation optimization: Skin tissue requires specialized fixation and permeabilization protocols to maintain protein integrity while allowing antibody access. Commonly used protocols include:

  • For paraffin sections: Formalin fixation followed by deparaffinization and antigen retrieval

  • For frozen sections: Acetone or methanol fixation

  • For cultured keratinocytes: 4% paraformaldehyde fixation with 0.1% Triton X-100 permeabilization

• Differentiation state considerations: Caspase-14 expression is tightly linked to keratinocyte differentiation, so experimental models must control for differentiation status:

  • In vitro: Use calcium switch protocols or air-liquid interface cultures to induce differentiation

  • In vivo: Sample from precisely defined epidermal layers

  • Compare undifferentiated basal cells with differentiated suprabasal and cornified cells

• Co-detection with differentiation markers: Pair Caspase-14 detection with established differentiation markers (e.g., involucrin, loricrin, filaggrin) to correlate expression with differentiation state.

• Preservation of skin barrier structures: Special attention to preserving stratum corneum structure is needed when studying Caspase-14's role in barrier formation.

• Functional readouts: Include functional assays of barrier integrity (e.g., transepidermal water loss measurements, dye penetration tests) alongside Caspase-14 expression analyses.

What approaches can be used to study post-translational modifications of CASP14?

Post-translational modifications (PTMs) of Caspase-14 are critical to understanding its regulation and function. The following approaches are recommended:

• Phosphorylation analysis: Use phospho-specific antibodies or phosphoproteomic techniques to identify phosphorylation sites that may regulate Caspase-14 activity.

• Ubiquitination detection: Employ immunoprecipitation with anti-ubiquitin antibodies followed by Caspase-14 detection, or vice versa, to assess ubiquitination status.

• PTM-specific enrichment techniques: Utilize titanium dioxide enrichment for phosphopeptides or lectin affinity chromatography for glycopeptides prior to mass spectrometry analysis.

• Site-directed mutagenesis: Create mutants of predicted PTM sites to assess functional consequences in cellular models.

• In vitro modification assays: Recombinant Caspase-14 can be subjected to in vitro kinase assays, ubiquitination assays, or other enzymatic reactions to identify potential modification sites.

• Mass spectrometry-based approaches: Implement targeted proteomics approaches to quantify PTM stoichiometry at specific residues of interest.

How has the CASP14 protein structure prediction competition influenced antibody research?

The 14th round of the Critical Assessment of Structure Prediction (CASP14) competition, particularly the breakthrough performance of AlphaFold2, has significant implications for antibody research:

• Structural epitope prediction: The unprecedented accuracy of AlphaFold2 models in CASP14, with GDT_TS scores above 90% even for difficult targets , enables more precise prediction of antibody epitopes based on protein structure.

• Fragment-based antibody design: CASP14 advancements have inspired new computational approaches for antibody design, such as fragment-based methods that target specific epitopes with complementary binding fragments . This approach allows for designing antibody CDR loops that target epitopes with high specificity.

• Improved binding site prediction: CASP14-derived models are being used for computational solvent mapping to identify binding hot spots and potential epitopes. Methods such as FTMap and FTSite can predict ligand binding sites with high accuracy, which can guide antibody development .

• Better homology modeling: When experimental structures of target proteins are unavailable, the improvement in protein structure prediction demonstrated in CASP14 enables more accurate homology models that can be used for epitope mapping and antibody design.

• Applicability to real-world targets: Analysis of CASP14 results showed that approximately 75% of CDRs (Complementarity-Determining Regions) designed based on AlphaFold2 models would be identical to those designed using experimental structures . This reliability extends to models with lower confidence, enabling antibody design against challenging targets.

What are the key distinctions between CASP14 (the competition) and CASP14 (Caspase-14) antibody research?

It's crucial for researchers to understand the difference between these two uses of "CASP14" to avoid confusion in literature searches and research planning:

How can computational models from CASP14 aid in developing better CASP14 (Caspase-14) antibodies?

The computational advances from CASP14 can be leveraged to develop improved Caspase-14 antibodies through several approaches:

• Epitope prediction optimization: The high-accuracy models from CASP14 can help identify surface-accessible epitopes specific to Caspase-14 that would not cross-react with other caspase family members.

• Fragment-based design for specificity: The fragment-based CDR design approach demonstrated in CASP14-related research can be applied to develop antibodies targeting specific conformational states of Caspase-14 (e.g., active vs. inactive).

• Binding site assessment: Methods used to evaluate binding site quality in CASP14 models, such as computational solvent mapping , can predict which epitopes on Caspase-14 would yield antibodies with optimal binding characteristics.

• Improved antigen design: Better structural predictions can guide the design of immunogens that present key Caspase-14 epitopes in their native conformation, potentially yielding antibodies with higher specificity and affinity.

• Assembly prediction for complex antigens: Insights from CASP14 assembly prediction assessments can help in designing antibodies that target protein-protein interaction surfaces of Caspase-14, potentially providing tools to modulate its biological activities.

• Structure-guided antibody engineering: Once antibodies against Caspase-14 are developed, structural models can guide affinity maturation through targeted mutations in the binding interface.

What is the recommended Western blot protocol for detecting Caspase-14 in skin samples?

Based on validated protocols from multiple sources, the following optimized Western blot procedure is recommended for detecting Caspase-14 in skin samples:

• Sample preparation:

  • Homogenize skin tissue in RIPA buffer containing protease inhibitors

  • Centrifuge at 12,000 g for 15 minutes at 4°C

  • Determine protein concentration using BCA or Bradford assay

  • Mix 20-30 μg protein with reducing sample buffer

• Gel electrophoresis and transfer:

  • Separate proteins on 12-15% SDS-PAGE gel

  • Transfer to PVDF membrane (0.45 μm pore size)

  • Confirm transfer efficiency with Ponceau S staining

• Immunoblotting:

  • Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Incubate with anti-Caspase-14 antibody at 1:1000-1:6000 dilution overnight at 4°C

  • Wash 3× with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

  • Wash 3× with TBST, 5 minutes each

  • Develop using ECL substrate and image

• Expected results:

  • Pro-Caspase-14: ~28-35 kDa band

  • Processed forms: may detect p20 and p10 subunits (~20 kDa and ~10 kDa respectively)

  • Positive controls: Mouse or rat skin tissue lysates

• Validation controls:

  • Loading control: β-actin or GAPDH

  • Negative control: Tissues known not to express Caspase-14

  • Specificity control: Peptide competition or CASP14 knockdown samples

What immunohistochemistry protocol provides optimal results for CASP14 detection in tissue sections?

For optimal immunohistochemical detection of Caspase-14 in tissue sections, the following protocol is recommended:

• Sample preparation:

  • Fix tissue in 10% neutral buffered formalin for 24 hours

  • Process and embed in paraffin

  • Section at 4-5 μm thickness

  • Mount on positively charged slides

• Deparaffinization and antigen retrieval:

  • Deparaffinize in xylene (2 × 5 minutes)

  • Rehydrate through graded ethanol series (100%, 95%, 70%)

  • Perform heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes

  • Cool to room temperature for 20 minutes

• Immunostaining:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal serum for 1 hour

  • Incubate with anti-Caspase-14 antibody at 1:50-1:200 dilution overnight at 4°C

  • Wash in PBS (3 × 5 minutes)

  • Apply HRP-polymer detection system according to manufacturer's instructions

  • Develop with DAB substrate

  • Counterstain with hematoxylin

  • Dehydrate, clear, and mount

• Expected results:

  • Positive staining in suprabasal layers of epidermis, particularly stratum granulosum and stratum corneum

  • Minimal or no staining in basal layer

  • Both cytoplasmic and nuclear staining may be observed

• Controls and validation:

  • Positive control: Normal human skin sections

  • Negative control: Primary antibody omission

  • Specificity control: Non-epithelial tissue sections

This protocol can be adapted for frozen sections with appropriate modifications to fixation and permeabilization steps.

What are common issues when working with Caspase-14 antibodies and how can they be resolved?

Researchers frequently encounter these challenges when working with Caspase-14 antibodies:

How can researchers address contradictory findings when studying Caspase-14?

When confronted with contradictory results regarding Caspase-14, systematic troubleshooting approaches can help resolve discrepancies:

• Antibody validation disparities: Different antibodies may recognize different epitopes or processing states of Caspase-14.

  • Solution: Validate findings using multiple antibodies targeting different regions of the protein .

  • Approach: Compare results from both monoclonal and polyclonal antibodies, and antibodies from different suppliers.

• Processing state variability: Caspase-14 exists in multiple forms (proenzyme, cleaved subunits) that may be differentially detected.

  • Solution: Use antibodies specific to different processing states or domains.

  • Approach: Incorporate positive controls with known processing states; use recombinant Caspase-14 standards.

• Species differences: Human, mouse, and rat Caspase-14 may exhibit different properties despite high homology.

  • Solution: Confirm antibody reactivity for your specific species .

  • Approach: Include species-matched positive controls; compare findings across species with appropriate controls.

• Context-dependent functions: Caspase-14 may exhibit different functions in different tissues or disease states.

  • Solution: Carefully define experimental context and avoid overgeneralizing findings.

  • Approach: Design experiments with appropriate tissue-specific and disease-specific controls.

• Technical variables: Differences in sample preparation, detection methods, or analytical approaches can yield contradictory results.

  • Solution: Standardize protocols and replicate findings using multiple technical approaches.

  • Approach: Validate key findings using orthogonal methods (e.g., complement protein detection with mRNA analysis).